Please login to the form below

Not currently logged in
Email:
Password:

Docetaxel

This page shows the latest Docetaxel news and features for those working in and with pharma, biotech and healthcare.

BMS scores first oesophageal cancer nod for Opdivo in Japan

BMS scores first oesophageal cancer nod for Opdivo in Japan

The MHLW approved Opdivo based on the results from the phase 3 ATTRACTION-3 trial, which evaluated the PD-1 inhibitor versus chemotherapy – docetaxel or paclitaxel – as a treatment for patients

Latest news

More from news
Approximately 1 fully matching, plus 106 partially matching documents found.

Latest Intelligence

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    In China there has been a rise in the use of Xeloda in combination with docetaxel as a second and third-line treatment.

  • Pharma deals during April 2013 Pharma deals during April 2013

    Bind more than $180.5m plus tiered royalties. And if that were not enough, the biotech recently secured $20m from its venture backers to fund phase II work on its

  • Detecting and managing NS

    Supported by sanofi-aventis, Succinct worked in close partnership with the UK Oncology Nursing Society (UKONS) to develop a range of patient-centred materials for those women receiving Taxotere (docetaxel) for

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics